Larimar Therapeutics Inc (LRMR) — Cash Flow-to-Debt Ratio
Larimar Therapeutics Inc (LRMR) has a Cash Flow-to-Debt Ratio of -1.16x as of June 2026, meaning its operating cash flow of $-44.03 Million could theoretically repay -1% of its total liabilities ($37.92 Million) in one year. See Larimar Therapeutics Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Larimar Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Larimar Therapeutics Inc across 14 annual periods. For the full cash flow conversion analysis, see LRMR operating cash flow.
Annual Cash Flow-to-Debt Ratio for Larimar Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Larimar Therapeutics Inc. Check LRMR cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.67x | $-113.20 Million | $67.76 Million | ▲ +32.9% |
| 2024 | -2.49x | $-70.76 Million | $28.41 Million | ▼ -5.8% |
| 2023 | -2.35x | $-33.46 Million | $14.21 Million | ▼ -32.4% |
| 2022 | -1.78x | $-27.57 Million | $15.50 Million | ▲ +39.8% |
| 2021 | -2.95x | $-42.10 Million | $14.25 Million | ▼ -5.0% |
| 2020 | -2.81x | $-42.20 Million | $14.99 Million | ▲ +26.9% |
| 2019 | -3.85x | $-22.70 Million | $5.89 Million | ▼ -113.1% |
| 2018 | -1.81x | $-51.49 Million | $28.49 Million | ▼ -12.6% |
| 2017 | -1.60x | $-43.78 Million | $27.29 Million | ▲ +69.5% |
| 2016 | -5.25x | $-51.98 Million | $9.89 Million | ▼ -76.4% |
| 2015 | -2.98x | $-59.55 Million | $20.00 Million | ▼ -37.9% |
| 2014 | -2.16x | $-28.24 Million | $13.08 Million | ▲ +58.0% |
| 2013 | -5.15x | $-15.00 Million | $2.92 Million | ▼ -11.0% |
| 2012 | -4.64x | $-13.59 Million | $2.93 Million | — |